The Effect of Required Injection Numbers during the First Year on the Clinical Course of Neovascular Age-related Macular Degeneration
Abdullah Ozkaya, Ihsan Yilmaz, Zeynep Alkin, Yalcin Karakucuk, Ahmet Taylan Yazici
Ophthalmology Research: An International Journal · pp. 397–405 · Published 23 Jul 2014
10.9734/OR/2014/11667Abstract
Aims: To evaluate the effect of injection number of ranibizumab on an as-needed treatment regimen during the first year of treatment on the clinical course of neovascular age-related macular degeneration (nAMD). Study Design: Retrospective study. Place and Duration of Study: Beyoglu Eye Training and Research Hospital. Department of Retina, between December 2009 and December 2011. Methodology: The newly diagnosed nAMD patients who were treated with intravitreal ranibizumab on an as-needed treatment regimen with a follow-up period of at least 24 months were included in the study. The patients were divided into three groups according to the required injection numbers during the first year; group 1, 3 injections; group 2, 4-5 injections; group 3≥5 injections. Main outcome measures were the change in best corrected visual acuity (BCVA), and central retinal thickness (CRT). Secondary outcome measure was the number of injections during the second year. Results: The study included 92 eyes of 87 patients. Group 1 consisted of 14 eyes (15.2%), group 2 consisted of 30 eyes (32.6%), and group 3 consisted of 48 eyes (52.2%). The visual outcomes seemed better in group 1; however, there was not a statistically significant difference among the three groups in regards of change in BCVA at all of the time points (p=0.4 for month 6, p=0.5 for month 12, p=0.6 for month 18, p=0.6 for month 24). There was not a statistically significant difference among the three groups in regards of change in CRT at all of the time points (p=0.2 for month 6, p=0.2 for month 12, p=0.1 for month 18, p=0.6 for month 24). The mean number of injections at month 12 and 24 was statistically different among the three groups (p<0.0001 for both). Conclusion: This study did not show a relationship between injection numbers and treatment outcomes in patients with nAMD on an as-needed treatment regimen. However there was a difference among the three groups in regard of visual acuity which was not statistically significant.
Cited by 0
No indexed citations yet.
Related research
- The Controversies Surrounding Bevacizumab and Ranibizumab — shares topic coverage
- The Epidemiology and Type of Macular Disease Seen in a Teaching Hospital in South-West, Nigeria — shares topic coverage
- Tachyphylaxis to ranibizumab in the Treatment of Age-related Macular Degeneration — shares topic coverage
- Assessment of Subfoveal Choroidal Thickness with SD-OCT in Eyes with Different Stages of Age-Related Macular Degeneration (AMD) — shares topic coverage
- Efficacy Analysis of Corneal Photo-vitrification (CPV) for Improved Vision of Age-related Macular Degeneration (AMD) Eyes — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
0
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.